According to p values the chances of phase 1 results being replicated in a larger study are close to 90%. If phase 2/3 study results are similar or improved the chance of FDA approval is pretty close to 100%. You would have to ascribe a probability of less than 8% to justify today's low share price. If you gave the drug a 50% chance of approval the SP should be a minimum of $1.50.
According to p values the chances of phase 1 results being...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.005(2.33%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 21.0¢ | $85.73K | 407.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 53482 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 278844 | 4 |
View Market Depth
| Last trade - 15.15pm 19/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |